N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.812 NOK 4.38% Market Closed
Market Cap: 918.2m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

Nykode Therapeutics ASA
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nykode Therapeutics ASA
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
N
Nykode Therapeutics ASA
OSE:NYKD
Cash & Cash Equivalents
$136.5m
CAGR 3-Years
-8%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Cash & Cash Equivalents
kr23.4m
CAGR 3-Years
-35%
CAGR 5-Years
-27%
CAGR 10-Years
41%
B
Bergenbio ASA
OSE:BGBIO
Cash & Cash Equivalents
kr174.8m
CAGR 3-Years
-30%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
Cash & Cash Equivalents
kr27.4m
CAGR 3-Years
-1%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Cash & Cash Equivalents
kr170m
CAGR 3-Years
-3%
CAGR 5-Years
50%
CAGR 10-Years
7%
T
Thor Medical ASA
OSE:TRMED
Cash & Cash Equivalents
kr29.6m
CAGR 3-Years
-60%
CAGR 5-Years
-42%
CAGR 10-Years
-5%
No Stocks Found

Nykode Therapeutics ASA
Glance View

Market Cap
918.2m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
0.181 NOK
Overvaluation 94%
Intrinsic Value
Price
N

See Also

What is Nykode Therapeutics ASA's Cash & Cash Equivalents?
Cash & Cash Equivalents
136.5m USD

Based on the financial report for Jun 30, 2024, Nykode Therapeutics ASA's Cash & Cash Equivalents amounts to 136.5m USD.

What is Nykode Therapeutics ASA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
29%

Over the last year, the Cash & Cash Equivalents growth was -21%. The average annual Cash & Cash Equivalents growth rates for Nykode Therapeutics ASA have been -8% over the past three years , 29% over the past five years .

Back to Top